Investigation by Kessler Topaz: uniQure Investors with Losses Urged to Reach Out

Investigation into uniQure N.V.'s Securities Violations

Kessler Topaz Meltzer & Check, LLP is currently conducting an investigation regarding potential violations of federal securities laws related to uniQure N.V., a biotechnology company specializing in gene therapy. This inquiry has arisen after uniQure disclosed significant setbacks regarding its investigational gene therapy product, AMT-130, which was intended for the treatment of Huntington's disease.

On November 3, 2025, uniQure released a press statement indicating that the U.S. Food and Drug Administration (FDA) had determined that the data provided for AMT-130 was insufficient to support the company's Biologics License Application (BLA) submission. This announcement was a major point of concern for investors, as it suggested that the FDA no longer agreed with uniQure's assessment of the adequacy of data from its Phase I/II studies. As a result, the timeline for submitting the BLA for AMT-130 was thrown into uncertainty.

The stock market reacted swiftly and severely to this announcement, with uniQure's stock price plummeting by over 50%. The share price fell from $67.69 on October 31, 2025, to a staggering $34.29 by the market close on November 3, 2025. This drastic decrease raised alarm bells among investors, prompting Kessler Topaz Meltzer & Check to encourage those with significant losses to consider legal action.

Kessler Topaz Meltzer & Check is reaching out to investors who might have suffered losses attributable to the aforementioned disclosures from uniQure. The firm is dedicated to protecting the rights of investors and ensuring that they are informed of their legal options. Investors who believe they have grounds for action due to the significant devaluation of their shares are urged to contact the firm. The legal team is available to discuss potential claims and outline the steps necessary to pursue a remedy.

Kessler Topaz Meltzer & Check, LLP is a recognized leader in the field of securities class actions and global investor protection. With a track record of successfully representing both individual and institutional investors, the firm takes pride in its ability to recover significant settlements in securities litigation cases. The team is known within the legal community and has received numerous awards and honors for its work in this area.

For those investors looking to learn more or to assess their potential for recovery, Kessler Topaz has made the process straightforward. Interested individuals may fill out an online form available on the firm's website or reach out directly to Jonathan Naji, Esq., at (484) 270-1453. Email correspondence is also welcomed at the firm’s designated address. By engaging with Kessler Topaz, investors can better understand their situation and determine if pursuing legal recourse is the right path forward.

As this investigation unfolds, it serves as a reminder of the importance of vigilance among investors, particularly in industries where regulatory approvals are critical to a company's success. uniQure's case, marked by unexpected developments, underscores the volatility inherent in biotech investments and the potential for substantial financial loss in the face of regulatory challenges.

For more information on this matter and the ongoing investigation into uniQure N.V., potential claimants can visit Kessler Topaz's website. The firm continues to advocate for investor rights and works rigorously to ensure that all stakeholders are treated fairly in the wake of significant financial events such as this one.